Griffith University

Biofilms are bacterial communities on surfaces within an extracellular matrix. Targeting biofilm-specific bacteria is crucial, and natural compounds with reported antibiofilm activity have garnered significant interest. The study evaluated the antibacterial and antibiofilm activity of Erythrina senegalensis leaf extract against multidrug-resistant (MDR) Gram-negative bacteria, including Salmonella typhimurium, Salmonella typhi, Salmonella enteritidis, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The leaf extract was prepared using aqueous and ethanol solvents, and qualitative phytochemical screening revealed the presence of various bioactive compounds such as tannins, saponins, cardiac glycosides, flavonoids, terpenoids, alkaloids, anthraquinone, reducing sugar, and ketones. A Kirby–Bauer disc diffusion assay was performed to test the susceptibility of antibiotics, and the antibacterial efficacy of the aqueous and ethanol extracts of E. senegalensis was determined using the cup-plate method, while the antibiofilm activities were determined using the crystal violet titer-plate method. The aqueous and ethanol extracts of Erythrina senegalensis revealed the presence of tannins, saponins, cardiac glycosides, flavonoids, terpenoids, alkaloids, anthraquinone, reducing sugar, and ketones. The study found that the Gram-negative bacteria isolates that were MDR were S. typhimurium, S. enteritidis, and P. aeruginosa, while K. pneumoniae was resistant to beta-lactam and fluoroquinolones, and S. typhi was sensitive to all antibiotics tested. Statistically, susceptibility to antibiotics had an inverse, weak, and significant relationship with biofilm production (r = −0.453, −0.106, −0.124, −0.106, −0.018, n = 10, p < 0.05). The aqueous extract showed good biofilm inhibition against K. pneumoniae and P. aeruginosa, and poor biofilm inhibition against S. enteritidis, while S. typhimurium and Salmonella typhi exhibited no biofilm inhibition. The ethanol extract did not demonstrate any antibiofilm activity against the tested Gram-negative pathogens. The study suggests that the Gram-negative bacteria’s capacity to form biofilms is negatively associated with their antibiotic resistance phenotypes, and the aqueous extract of E. senegalensis exhibited moderate antibiofilm activity against K. pneumoniae, P. aeruginosa, and S. enteritidis.

Oyibo Joel Enupe; Christiana Micah Umar; Manbyen Philip; Emmanuel Musa; Victor Baba Oti; Asif Khaliq. Evaluation of the Antibacterial and Antibiofilm Activity of Erythrina senegalensis Leaf Extract Against Multidrug-Resistant Bacteria. Acta Microbiologica Hellenica 2024, 69, 258 -273.

Oyibo Joel Enupe, Christiana Micah Umar, Manbyen Philip, Emmanuel Musa, Victor Baba Oti, Asif Khaliq. Evaluation of the Antibacterial and Antibiofilm Activity of Erythrina senegalensis Leaf Extract Against Multidrug-Resistant Bacteria. Acta Microbiologica Hellenica. 2024; 69 (4):258-273.

Oyibo Joel Enupe; Christiana Micah Umar; Manbyen Philip; Emmanuel Musa; Victor Baba Oti; Asif Khaliq. 2024. "Evaluation of the Antibacterial and Antibiofilm Activity of Erythrina senegalensis Leaf Extract Against Multidrug-Resistant Bacteria." Acta Microbiologica Hellenica 69, no. 4: 258-273.

Introduction: Clinical trials are essential to the advancement of clinical therapies that improve the outcomes of people with cancer. However, enrollment in clinical trials remains a challenge. The Clinical Trial Navigator [CTN] Program was designed to address the current gap in the cancer care journey by assisting with the clinical trials search process. Methods: Between March 2019 and July 2024, applicants of the CTN program included people with cancer, their family members, and/or their care team. Applicants entered the CTN program through a REDCap^® survey that collected the patient’s medical history. A final curated list of potential clinical trials was provided to the applicant. Metrics of success included clinical trial referral and enrollment, and we examined the factors that impacted these outcomes. Results: A total of 445 people with cancer applied to the CTN program during the study. Of the 262 patients with referral and enrollment information, a trial referral occurred in 27.5% [n = 72]. Of the 72 patients who were referred to a clinical trial, 13 [18.1%] were enrolled, 9 [12.5%] are pending enrollment, and 50 [69.4%] were not enrolled. We identified a potential trial for 88% of applicants, with a median of one potential trial per patient. Physicians were highly involved as applicants. Interpretation: The CTN program is successful in searching for clinical trials for people with cancer. Ongoing implementation into other Canadian sites, assessments of patient-reported outcomes, website and social media campaigns, and research into the factors that impact referral and enrollment are underway.

Mahmoud Hossami; Rhonda Abdel-Nabi; Farwa Zaib; Kayla Touma; Renee Nassar; Sanghyuk Claire Rim; Milica Paunic; Olla Hilal; Pratham Gupta; Roaa Hirmiz; Michael Touma; Govana Sadik; Emmanuel Akingbade; Depen Sharma; Swati Kalia; Rija Fatima; Anthony Luginaah; Ibrahim Mohamed; Rong Luo; Megan Delisle; Caroline Hamm. Facilitation of Enrollment onto Cancer Clinical Trials Using a Novel Navigator-Assisted Program: A Cross-Sectional Study. Current Oncology 2024, 31, 7144 -7154.

Mahmoud Hossami, Rhonda Abdel-Nabi, Farwa Zaib, Kayla Touma, Renee Nassar, Sanghyuk Claire Rim, Milica Paunic, Olla Hilal, Pratham Gupta, Roaa Hirmiz, Michael Touma, Govana Sadik, Emmanuel Akingbade, Depen Sharma, Swati Kalia, Rija Fatima, Anthony Luginaah, Ibrahim Mohamed, Rong Luo, Megan Delisle, Caroline Hamm. Facilitation of Enrollment onto Cancer Clinical Trials Using a Novel Navigator-Assisted Program: A Cross-Sectional Study. Current Oncology. 2024; 31 (11):7144-7154.

Mahmoud Hossami; Rhonda Abdel-Nabi; Farwa Zaib; Kayla Touma; Renee Nassar; Sanghyuk Claire Rim; Milica Paunic; Olla Hilal; Pratham Gupta; Roaa Hirmiz; Michael Touma; Govana Sadik; Emmanuel Akingbade; Depen Sharma; Swati Kalia; Rija Fatima; Anthony Luginaah; Ibrahim Mohamed; Rong Luo; Megan Delisle; Caroline Hamm. 2024. "Facilitation of Enrollment onto Cancer Clinical Trials Using a Novel Navigator-Assisted Program: A Cross-Sectional Study." Current Oncology 31, no. 11: 7144-7154.

Guanqi Liu; Ruidi Xia; Mixiao Gui; Linjun Zhang; Xuan Zhou; Junlong Xue; Yihua Cai; Yang Cao; Yin Xiao; Zetao Chen. Turn Hood into Good: Recycling Silicon from Mesoporous Silica Nanoparticles through Magnesium Modification to Lower Toxicity and Promote Tissue Regeneration. 2024 .

Guanqi Liu, Ruidi Xia, Mixiao Gui, Linjun Zhang, Xuan Zhou, Junlong Xue, Yihua Cai, Yang Cao, Yin Xiao, Zetao Chen. Turn Hood into Good: Recycling Silicon from Mesoporous Silica Nanoparticles through Magnesium Modification to Lower Toxicity and Promote Tissue Regeneration. . 2024; ():.

Guanqi Liu; Ruidi Xia; Mixiao Gui; Linjun Zhang; Xuan Zhou; Junlong Xue; Yihua Cai; Yang Cao; Yin Xiao; Zetao Chen. 2024. "Turn Hood into Good: Recycling Silicon from Mesoporous Silica Nanoparticles through Magnesium Modification to Lower Toxicity and Promote Tissue Regeneration." , no. : .